Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03621020
Other study ID # TQPL-RD-121-1
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2018
Est. completion date February 14, 2020

Study information

Verified date February 2020
Source Hikari Dx, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth.


Description:

This study will measure primary hemostatic ability using the T-TAS 01 System with PL chip, with a comparison to clinical truth. The study will be conducted at 3 locations in the United States and will enroll approximately 335 subjects. The following subject populations will be enrolled into the study (expected enrollment numbers indicated in parentheses):

- Ostensibly healthy subjects without primary hemostasis abnormalities, e.g. a "healthy platelet" normal control population (N = 150)

- Subjects taking 81+ mg daily aspirin (N = 81)

- Subjects taking dual antiplatelet therapy (N = 51)

- Subjects with von Willebrand disease (vWD; N = 47)

- Subjects with Glanzmann's thrombasthenia (N = 5)

Subjects may be recruited either prospectively or based on their simultaneous participation in other studies involving blood collection, provided that the enrollment criteria. Blood samples will be collected after enrollment and subject participation will be complete after blood samples are collected and all necessary information is collected to complete the case report form (CRF). Blood sample testing with T-TAS 01 will occur locally at each investigational site. Blood sample testing for clinical truth assessment may be tested either locally or remotely, depending on the local availability of the various tests used for determining clinical truth.


Recruitment information / eligibility

Status Completed
Enrollment 307
Est. completion date February 14, 2020
Est. primary completion date February 14, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Normal Controls:

Inclusion Criteria

- Males and females age 21 years or older.

- Able and willing to provide written informed consent. Exclusion Criteria

- Abnormal results from assays used to establish clinical truth (retrospective exclusion).

- Hospitalization or doctor's visits within prior 30 days, except for routine checkup/physical examination.

- Use of antiplatelet therapy within the past 14 days, e.g. aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol.

- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.

- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.

- History of anemia.

- Known thrombocytopenia (platelet count < 100,000/µL).

- Significant renal dysfunction or dialysis.

- History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann's thrombasthenia or Bernard-Soulier syndrome.

- History of hemophilia or bleeding disorders.

- History of bleeding, with Bleeding Score = 5 (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories:

- Epistaxis

- Cutaneous bleeding

- Bleeding from minor wounds

- Bleeding from oral cavity

- Gastrointestinal bleeding

- Bleeding from tooth extraction

- Surgical bleeding

- Menorrhagia

- Post-partum hemorrhage

- Muscle hematoma

- Hemarthrosis

- Central nervous system bleeding

- Females who are in the last trimester of pregnancy, or are breastfeeding.

- Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.

- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.

- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.

Antiplatelet Therapy Subjects:

Inclusion Criteria

- Males and females age 21 years or older.

- Continuous daily ingestion of one of the following antiplatelet therapy regimens:

- 81 mg or higher aspirin

- 81 mg or higher aspirin plus 75 mg daily clopidogrel

- 81 mg or higher aspirin plus 10 mg daily prasugrel

- 81 mg aspirin plus 180 mg daily ticagrelor

- Able and willing to provide written informed consent. Exclusion Criteria

- Use of antiplatelet therapy besides aspirin (e.g. clopidogrel, prasugrel, ticagrelor, cilostazol, abciximab, eptifibatide) within the past 14 days.

- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.

- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.

- Significant renal dysfunction or dialysis.

- Known thrombocytopenia (platelet count < 100,000/µL).

- History of platelet disorders e.g. von Willebrand factor deficiency, Glanzmann thrombasthenia or Bernard-Soulier syndrome.

- History of hemophilia or bleeding disorders.

- Females who are in the last trimester of pregnancy, or are breastfeeding.

- Known active gastrointestinal disease including peptic ulcers, gastro-esophageal reflux disease (GERD), and hyperacidity.

- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.

- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.

vWD Subjects: Inclusion Criteria

- Males and females age 21 years or older.

- Prior diagnosis of von Willebrand disease type 1, 2A, 2B, 2M, or 3

- History of bleeding, with Bleeding Score = 5, which is 99% specific for vWD (Tosetto J Thromb Haemost 2006). See Appendix A. Scores will be assigned based on health history according to the following categories:

- Epistaxis

- Cutaneous bleeding

- Bleeding from minor wounds

- Bleeding from oral cavity

- Gastrointestinal bleeding

- Bleeding from tooth extraction

- Surgical bleeding

- Menorrhagia

- Post-partum hemorrhage

- Muscle hematoma

- Hemarthrosis

- Central nervous system bleeding

- Able and willing to provide written informed consent. Exclusion Criteria

- Prior diagnosis of von Willebrand disease type 2N

- Receiving desmopressin or vWF replacement therapy within the past 2 weeks.

- Use of antiplatelet therapy within the past 14 days.

- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.

- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.

- Significant renal dysfunction or dialysis.

- Known thrombocytopenia (platelet count < 100,000/µL).

- Females who are in the last trimester of pregnancy, or are breastfeeding.

- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.

- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.

Glanzmann's Thrombasthenia Subjects:

Inclusion Criteria

- Males and females age 21 years or older.

- Prior diagnosis of Glanzmann's thrombasthenia

- History of bleeding.

- Able and willing to provide written informed consent. Exclusion Criteria

- Use of antiplatelet therapy within the past 14 days.

- Use of anticoagulant drugs within the past 14 days, e.g. heparin, bivalirudin, warfarin, rivaroxaban, and apixaban.

- Use of certain nonsteroidal anti-inflammatory drugs (NSAIDs) such as celecoxib, rofecoxib, etc. within the past 14 days.

- Significant renal dysfunction or dialysis.

- Known thrombocytopenia (platelet count < 100,000/µL).

- Females who are in the last trimester of pregnancy, or are breastfeeding.

- Currently participating in a study involving an investigational drug or compound known to affect coagulation or hemostasis.

- Subjects with significant past medical history as determined by the Investigator that would pose safety concerns or interfere with the study goals.

Study Design


Intervention

Diagnostic Test:
T-TAS 01 PL Chip
Flow chamber microchip system specific for measuring primary hemostatic ability
PFA-100 Col/Epi and Col/ADP
System for measuring platelet dysfunction

Locations

Country Name City State
France Centre Hospitalier Universitaire de Bordeaux Bordeaux CA
United States Sinai Hospital of Baltimore Baltimore Maryland
United States Inova Heart and Vascular Institute Falls Church Virginia
United States University of Iowa Iowa City Iowa
United States Inova Cardiology Baltimore Lutherville Maryland
United States San Francisco General Hospital San Francisco California

Sponsors (2)

Lead Sponsor Collaborator
Hikari Dx, Inc. Fujimori Kogyo Co., Ltd.

Countries where clinical trial is conducted

United States,  France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity and specificity for detecting defects in primary hemostasis Sensitivity and specificity of the T-TAS 01 PL chip assay against clinical truth Baseline
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1